Related Experiment Video
Updated: Jun 21, 2026

Quantitating Iron Transport Across the Mouse Placenta In Vivo Using Nonradioactive Iron Isotopes
Published on: May 10, 2022
Irinotecan use during pregnancy
Justin Taylor1, Adanna Amanze, Elaine Di Federico
1From the Division of Hematology Oncology, University of New Mexico Cancer Center, and Department of Gynecology and Obstetrics, University of New Mexico, Albuquerque, New Mexico.
Background:
Ovarian tumors during pregnancy are rare. There is sparse clinical evidence about the safety of chemotherapy in this situation.
Case:
A 34-year-old woman was diagnosed by ultrasonography at 15 1/2 weeks of pregnancy with a Krukenberg tumor. She was treated with surgical removal and 10 courses of the combination of 5-fluorouracil, folinic acid, and irinotecan every 2 weeks until the 36th week of her pregnancy. The neonate was born without complications, and at age 4 months, showed normal development and no teratogenic effects.
Conclusion:
In this case, irinotecan started at the second trimester and was safely used at full adjuvant dose.
Related Concept Videos
Chemotherapy-Induced Nausea and Vomiting: 5-HT3 Receptor Antagonists
Teratogenicity
Radiological Investigation I: X-ray and CT
Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists
Intrauterine Drug Delivery Systems
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents